Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-25-009631
Filing Date
2025-04-02
Accepted
2025-04-02 16:15:17
Documents
1
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 form4-04022025_040410.html 4  
1 form4-04022025_040410.xml 4 3376
  Complete submission text file 0001415889-25-009631.txt   5126
Mailing Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807
Business Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Issuer) CIK: 0001566044 (see all company filings)

EIN.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O FOAMIX PHARMACEUTICALS LTD. 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK REHOVOT L3 76704
Business Address
Harsch Mutya (Reporting) CIK: 0001727809 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38356 | Film No.: 25804679